Cel Sci CVM
NYSE CVM
$1.78 +0.08 (+4.90%)
As of: Sep 29, 2026 · 3:58 PM EDT

Cel Sci (CVM) EBIT Margin (2010 - 2017)

Updated

Cel Sci (CVM) reported EBIT Margin of -27366.26% for fiscal Q3 2017 (quarter ended Jun 30, 2017), down 22822.20 percentage points from -4544.06% a year earlier.

Analysis

Cel Sci (CVM) EBIT Margin (2010 - 2017) Analysis & Trends

Over the twelve months ended Jun 30, 2017, Cel Sci's EBIT Margin came in at -9481.25%.

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) EBIT Margin (Qtr)
1 Johnson & Johnson 655.56 Bn 574.09 Bn 17.26 Bn 28.21%
2 AbbVie 470.94 Bn 444.10 Bn 12.70 Bn 37.86%
3 Merck 367.14 Bn 321.57 Bn 12.21 Bn -3.52%
4 Novartis Ag 280.33 Bn 236.20 Bn 11.24 Bn 32.97%
5 Astrazeneca 257.78 Bn 231.34 Bn 12.86 Bn 20.57%
6 Amgen 226.04 Bn 181.44 Bn 7.24 Bn 34.95%
7 Gilead Sciences 188.89 Bn 163.01 Bn 6.22 Bn -133.21%
8 Pfizer 163.75 Bn 110.70 Bn 10.94 Bn 28.37%
9 Vertex Pharmaceuticals 133.68 Bn 105.69 Bn 2.84 Bn 37.40%
10 Cel Sci 3.11 Mn -22.54 Mn - -
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2017 -27,366.26%
Jun 30, 2016 -4,544.06%
Jun 30, 2011 -6,260.41%
Jun 30, 2010 -10,984.01%
API Access

Cel Sci EBIT Margin API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=ebit-margin&ticker=CVM&period=max&api_key=YOUR_API_KEY